172966-53-9

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 41979-39-9 4-piperidone hydrochloride 
• 439097-58-2 1-(2-fluoro-4-nitro-phenyl)piperidin-4-one 
• 252336-82-6 4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluoronitrobenzene 

Downstream Products

• 685570-78-9 N-[[(5S)-3-[3-fluoro-4-(4-methylcarbonyl-methylidene-5-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-84-7 N-[[(5S)-3-[3-fluoro-4-(4-(2-oxoethylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 596136-34-4 N-[[(5S)-3-[3-fluoro-4-(4-cyanomethylidene-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-79-0 N-[[(5S)-3-[3-fluoro-4-(4-(1-ethoxycarbonyl-ethylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-93-8 N-[[(5S)-3-[3-fluoro-4-(4-(2-acetoxy-propylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-92-7 N-[[(5S)-3-[3-fluoro-4-(4-(2-hydroxy-propylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 685570-88-1 N-[[(5S)-3-[3-fluoro-4-(4-(2-hydroxyimino-ethylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 648919-97-5 N-[[(5S)-3-[3-fluoro-4-((4-(1-ethoxycarbonyl-cyano)-methylidene)-piperidinyl)-phenyl]-2-oxo-5-oxazolidinyl]-methyl]-acetamide 
• 648919-89-5 (S)-N-{3-[4-(4-(1,1-dicyano-methylidene)-piperidin-1-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 
• 853796-30-2 (S)-N-{3-[4-(4,8-diaza-1-thia-spiro[4.5]dec-8-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 
• 172966-62-0 (S)-N-{3-[3-fluoro-4-(4-methoxycarbonylhydrazono-piperidin-1-yl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 

Relevant academic research and scientific papers

Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety

In this article, a series of novel oxazolidinone derivatives containing a piperidinyl moiety was designed and synthesized. Their antibacterial activities were measured against S. aureus, MRSA, MSSA, LREF and VRE by MIC assay. Most of them exhibited potent activity against Gram-positive pathogens comparable to linezolid. Among them, compound 9h exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metabolism in human liver microsome. The most promising compound 9h, which showed remarkable antibacterial activity against S. aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.25–1 μg/mL, was an interesting candidate for further investigation.

OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS

A compound of Formula I: or a pharmaceutically acceptable salt thereof, which is antimicrobial agents, effective against various human and veterinary pathogens, including gram positive aerobic organisms, gram negative organisms, and anaerobic organisms.

Oxazolidinone derivatives and pharmaceutical compositions

A compound of Formula I: STR1 or a pharmaceutically acceptable salt thereof, which is antimicrobial agents, effective against various human and veterinary pathogens, including gram positive aerobic organisms, gram negative organisms, and anaerobic organisms.

Oxazolidinone derivatives and pharmaceutical compositions containing them

The present invention provides agents having high antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel oxazolidinone derivatives represented by chemical formula (I), or pharmaceutically acceptable salts thereof, as well as antimicrobial compositions containing said derivatives or salts thereof as active ingredients. STR1